官方服务：
资源简介：
Relapses after medical treatment.
应用场景：
创建时间：
2015-12-02
相关数据集
Operative and post-operative outcomes of the biochemical recurrence versus no recurrence groups.
Operative and post-operative outcomes of the biochemical recurrence versus no recurrence groups.
NIAID Data Ecosystem70
Overview of included RRMS phase-3 trials (n = 13).
RRF = Rate of relapse free patients after 2 years, SE = Standard error, ARR = Annualized relapse rate over 2 years, SD = Standard deviation, 2001/2005 indicates the use of the original 2001 McDonald c
Figshare2015-12-02 更新50
Supplementary Material for: A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression
Introduction: In a multicenter, open-label, parallel-group, randomized, phase 2 study for pretreated advanced hepatocellular carcinoma (HCC), camrelizumab showed potent antitumor activity and acceptab
NIAID Data Ecosystem50
35549e9c-f1f9-4722-8181-ec8c3cd8fbbf - samples
Whole genome sequencing of AML blood or bone marrow at presentation and remission for 5 patients. Relapse samples are included for 2 patients, totaling 12 WGS BAM files.EGA dataset EGAD00001005120
NIAID Data Ecosystem70
COR peak week 1 improvement and COR peak week 5 improvement.
Response and remission rates after 5 weeks of treatment in 40 depressed patients (sample 2) treated with either reboxetine (n = 20) or mirtazapine (n = 20) [33]. Patients are subdivided into COR peak
NIAID Data Ecosystem50
